Kinetikos wins grant to apply exoskeleton space technology to the treatment of lower limb impairments
Kinetikos was awarded a grant by Cross4Health, sponsored by the European Commission, to develop iWalkU, a continuum health solution that applies spaceflight exoskeleton technology - Typically used to recondition astronauts after long exposure to microgravity environments in outer space - to the treatment of individuals with lower limb impairments.
With iWalkU, Kinetikos continues to pursue its mission of revolutionising clinical decision-making for mobility disorders. By collaborating on a web-based platform connected to an easy-to-use exoskeleton, iWalkU provides a safe, remote, and effective care of terrestrial mobility in impaired individuals, in a unique combination of rehabilitation expertise with bio and aerospace technologies. Once implemented, it will allow healthcare providers to remotely monitor and update patients’ exoskeleton-assisted exercise programs to be carried out at their own homes. Patients’ behaviour and performance will be captured by specialised inertial sensors and sent to a processing unit that uses a machine learning pipeline to pre-process and compare the received signal with the patient’s past behaviour. A detailed characterization of the performed exercises and daily activities will then be uploaded to iWalkU database, and reported in real time to the healthcare provider and the patient.
Cross4Health is a project funded by the European Commission Horizon 2020 Programme aimed at fostering collaboration between aerospace, biotechnology and medical device ventures. This grant represents yet another innovative collaboration between Kinetikos and other companies (the Austrian Space Forum and the FisioManual rehabilitation clinic), bringing together the expertise from different fields and applying human motion analysis and machine learning to help uncover the mechanisms that trigger the decline from healthy mobility to pathological movement.
This project was funded under the Sub-grant Agreement N.º 2018/A03Back to News